LONDON - A major UK trial exploring the possibility of a mix-and-match approach to Covid vaccination is being expanded to include the Moderna and Novavax jabs.
Scientists behind the Com-COV study, led by the University of Oxford, hope that combining vaccines could give “broader, longer-lasting immunity” against the coronavirus and new variants.
Using different brands of vaccination for first and second doses would also give more flexibility to the vaccine rollout.